Reportedly providing enhanced imaging of structural heart disease, the minimally invasive X11 4t Mini 3D TEE ultrasound transducer facilitates use of the technology in smaller pediatric patients as well as high-risk ICU patients.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the X11 4t Mini 3D TEE transducer, a device that may broaden the use of transesophageal echocardiography (TEE) to patients in intensive care units (ICUs) and smaller pediatric patients.
The enhanced imaging capability with three-dimensional TEE in assessing structural heart disease can help save lives, according to Philips, the manufacturer of the X11 4t Mini 3D TEE transducer. The company added that the technology can also be beneficial for minimally invasive heart surgery cases.
Noting the device’s pill-shaped design and a 35 percent smaller size than other TEE transducers, Philips said the X11 4t Mini 3D TEE transducer enables clinicians to utilize the technology for ICU patients as well as smaller pediatric patients.
“In many of our smallest patients undergoing complex intracardiac procedures like valve repairs, 3D TEE will give us a new and much needed perioperative tool,” noted Brian Soriano, M.D., FASE, a pediatric cardiologist at Seattle Children’s Hospital.
“For example, the X11-4t (Mini 3D TEE transducer) can help us visualize atrioventricular valves en face. In many cases, this is a view that is difficult to achieve with traditional 2D TEE. 3D TEE will also be a more effective tool to communicate with the surgeons and will enable us to give good ‘surgeon views’ of intracardiac structures.”
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.